(Q51034792)

English

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.

scientific article published on 17 November 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

B Keam

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J Koh

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

H J Cho

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Y K Jeon

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

T M Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S H Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

D S Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

D W Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

D H Chung

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

17 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

348-354

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403583%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU530

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51034792&oldid=1966797056"